

Slovakia Ministry of Health meeting with Amylyx Pharmaceuticals

Date: April 27, 2023

Participants (Ministry of Health):

- Peter Polak, Director General, Section of Pharmacy and Drug Policy, Ministry of Health
- [MoH to add additional names]

Participants (Amylyx Pharmaceuticals):

- Lugdivine Le Dez, Head Patient Advocacy and Government Affairs, EMEA, Amylyx Pharmaceuticals
- Leo Strican, Head of Market Access, EMEA, Amylyx Pharmaceuticals

Meeting Notes:

- Amylyx team introductions;
- Ministry of Health team introductions;
- Amylyx provided an overview of the company;
- Amylyx briefed the Ministry of Health on ALS, disease progression, diagnosis, and standard of care;
- Amylyx provided an overview of its investigational therapy AMX0035 and presented clinical study data;
- Amylyx informed the Ministry of Health that AMX0035 is approved for treatment in the United States and Canada, and that the company has applied for conditional marketing authorization with the European Medicines Agency;
- Amylyx informed the Ministry of Health on its ongoing clinical Phase III clinical trial.